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Abstract
The  renin-angiotensin  system  (RAS)  constitutes  a  key  hormonal  system  in  the
physiological  regulation of  blood pressure via peripheral  and central  mechanisms.
Dysregulation  of  the  RAS  is  considered  a  major  factor  in  the  development  of
cardiovascular  pathologies,  and  pharmacologic  blockades  of  this  system  by  the
inhibition of angiotensin-converting enzyme (ACE) or antagonism of the angiotensin
type 1 receptor (AT1R) are effective therapeutic regimens. The RAS is now defined as
a system composed of different angiotensin peptides with diverse biological actions
mediated by distinct receptor subtypes. The classic RAS comprises the ACE-Ang II-
AT1R  axis  that  promotes  vasoconstriction,  water  intake,  sodium  retention  and
increased oxidative stress, fibrosis, cellular growth, and inflammation. The nonclass-
ical or alternative RAS is composed primarily of the ACE2-Ang-(1-7)-AT7R pathway
that opposes the Ang II-AT1R axis. In lieu of the complex aspects of this system, the
current review assesses the enzymatic cascade of the alternative Ang-(1-7) axis of the
RAS.
Keywords: angiotensin-(1-7), neprilysin, dipeptidyl peptidase 3, ACE, ACE2, renin
1. Introduction
The renin-angiotensin system (RAS) has been long defined as a circulating endocrine system
composed of  an  enzymatic  cascade  that  includes  renin  to  initiate  the  RAS through the
conversion of the large precursor protein angiotensinogen (>350 amino acids) to the inactive
decapeptide Ang I and the subsequent generation of the bioactive octapeptide Ang II by
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angiotensin-converting enzyme (ACE) (Figure 1).  Ang II binds to the angiotensin type 1
receptor (AT1R) to mediate both peripheral and central mechanisms in the regulation of blood
pressure.  Activation  of  the  ACE-Ang  II-AT1R  pathway  is  also  associated  with  various
pathological  responses  including  fibrosis,  inflammation,  metabolic  dysregulation,  heart
failure, cancer, aging, and diabetic injury [1–5].  Indeed, the targeting of this pathway by
biochemical approaches that block the formation of Ang II through ACE inhibitors or binding
of Ang II to the AT1R by receptor antagonists is an effective therapy for the treatment of
cardiovascular  disease.  It  is  now  evident  that  these  therapies  have  revealed  alternative
pathways within the RAS that may contribute to the beneficial actions of the RAS blockade.
For example, the targeting of ACE reduces Ang II expression, but markedly enhances the
circulating levels of Ang-(1-7), a ligand for the AT7/MasR that generally opposes the actions
of the Ang II-AT1R pathway [6, 7]. The chronic treatment with AT1R antagonists may also
increase the formation of Ang-(1-7) through ACE2, as well as shunt Ang II to the AT2R pathway
that shares similar properties to the Ang-(1-7) system [8, 9]. Since the RAS is now viewed as
a  more  complex  array  of  components  that  can  be  functionally  partitioned  into  distinct
receptors and peptide ligands, we present an overview of the peptidases the may constitute
the alternative Ang-(1-7) axis of the RAS. We include a discussion of renin, ACE, and chymase
as they pertain to the formation of the substrates Ang I and Ang II for the direct processing to
Ang-(1-7), as the well as the role of ACE to metabolize Ang-(1-7).
Figure 1. Processing cascade for angiotensin-(1-7). Renin cleaves angiotensinogen to Ang I which is further processed
to the biologically active peptides Ang II by ACE or chymase (CHYM). Ang II undergoes further processing by the
carboxypeptidase ACE2 to form Ang-(1-7). Ang-(1-7) is formed directly through non-Ang II pathways by the direct
processing of Ang I by the endopeptidases neprilysin (NEP) and thimet oligopeptidase (TOP). Ang-(1-7) is subse-
quently metabolized by ACE to Ang-(1-5) and dipeptidyl peptidase 3 (DPP3) to Ang-(3-7) and Ang-(5-7). Adapted
from Chappell [54].
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2. Renin
Renin [EC 3.4.23.15] belongs to the family of aspartyl-type acid proteases (molecular size: 30–
40 kDa); however, the protease exhibits a more neutral pH optima of 6.5–8.0. The only known
substrate for renin is angiotensinogen, and renin cleaves off the N-terminal portion of angio-
tensinogen to form the inactive peptide Ang I. The formation of Ang I is considered the
enzymatic event that initiates the RAS cascade (Figure 1). The enzyme is synthesized pre-
dominantly in the juxtaglomerular (JG) cells of the kidney and is stored in both inactive
(prorenin) and active forms for subsequent release into the afferent arteriole to reach the
circulation. The collecting duct (CD) cells are another source of renin within the kidney that
primarily secretes the active form of renin from the apical aspect of the principal cells into the
tubular fluid [10, 11]. The distal secretion of renin into the tubular fluid would presumably
contribute to the processing of angiotensinogen that may arise from either proximal tubule
synthesis or apical release or the glomerular filtration of the protein. Interestingly, the regula-
tion of JG renin appears to be distinct from CD renin as Ang II reduces JG renin release and
synthesis constituting the classic short-loop negative feedback system for RAS activation,
whereas the peptide stimulates CD renin release suggesting a positive feedback system for
renin in the distal nephron [12, 13].
There is evidence for alternative gene products of renin expressed in the kidney, brain, heart,
and adrenal gland [14–17]. These products arise from an alternative start site for renin
transcription that is situated downstream from the typical start site and yields a shorter, but
active form of the enzyme. The truncated form of renin lacks the secretory signal of the protein
and the enzyme is not secreted, but resides within the cell. Peters and colleagues find that
truncated renin specifically localized to the mitochondria and that the active form of renin, but
not prorenin, was internalized by mitochondria [14, 18, 19]. The overexpression of the active
renin isoform protected the cells under high glucose conditions and this effect was not reversed
by the renin inhibitor aliskerin or an AT1R antagonist suggesting that the beneficial effects may
not reflect activation of the Ang II-AT1R axis [20]. In support of these findings, we recently
reported the presence of active renin in isolated mitochondria from the sheep renal cortex [21].
In this case, we also quantified the mitochondrial levels of both Ang II and Ang-(1-7) (50–60
fmol/mg protein), which may indicate that the intracellular form of renin contributes to the
cellular expression of angiotensin peptides within the kidney [21]. In the renal NRK-52
epithelial cell line, immunocytochemical staining for renin was evident in the nucleus of these
cells [22]. Renin activity as measured by aliskerin-sensitive inhibition of Ang I formation from
angiotensinogen was also evident in isolated nuclei in the renal epithelial NRK-52 cells, as well
as quantifiable levels of Ang I, Ang II, and Ang-(1-7) [22]. In confirmation of intracellular renin
within the kidney, Ishigami and colleagues report a truncated renin transcript expressed in the
proximal tubules of the mouse kidney [16]. Overexpression of the renin isoform within the
proximal tubules was associated with a sustained elevation in blood pressure and no change
in the circulating levels of renin [16]. Although the intracellular distribution of the renin
isoform was not ascertained, the fact that overexpression of tubular renin augmented blood
pressure is consistent with previous studies demonstrating that the increased expression of
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proximal tubule angiotensinogen, the AT1R, or intracellular Ang II also resulted in a sustained
increase in blood pressure [23–28].
3. Angiotensin-converting enzyme
The predominant pathway of the classical RAS for the conversion of Ang I to the bioactive
peptide Ang II is catalyzed by the metallopeptidase ACE [EC 3.4.15.1], a dipeptidyl carboxy‐
peptidase that cleaves two residues from the carboxy terminus of Ang I (Figure 1). The
peptidase is a membrane‐bound, glycosylated protein (120–180 kDa) ubiquitously expressed
in multiple tissues [29]. Soluble forms of the enzyme are present in the circulation, cerebro‐
spinal fluid (CSF), lymph fluid, and urine that fully retain peptidase activity [29]. The soluble
form of ACE arises from the hydrolysis of the membrane‐anchoring or stalk region of the
protein that may reflect the processing by A Disintegrin and Metalloproteinase (ADAM) family
of metalloenzymes, although the precise role of ACE shedding in cardiovascular disease is
presently unclear. Somatic ACE is characterized by two active sites termed N and C terminal
domains that likely arose from the gene duplication of germinal or testicular ACE that contains
only the single C terminal‐active site. Importantly, in addition to forming Ang II, ACE degrades
a number of other peptides that exhibit cardiovascular actions including bradykinin, substance
P, acetyl‐SDKP, and Ang‐(1‐7) [29]. Indeed, the cardioprotective effects of ACE inhibitors may
reflect the protection of these peptides from metabolism in addition to the blockade of Ang II
formation. We showed that ACE hydrolyzes Ang‐(1‐7) to the pentapeptide Ang‐(1‐5) and that
ACE inhibition markedly reduced the clearance of the peptide [30, 31]. The reduced metabo‐
lism of Ang‐(1‐7) likely contributes to the elevation in circulating levels of Ang‐(1‐7) following
the chronic treatment with ACE inhibitors in experimental animals and in humans [32].
Moreover, treatment with an ACE inhibitor was required to clearly demonstrate the accumu‐
lation of Ang‐(1‐7) derived from either Ang II or Ang I in isolated proximal tubules [33]. These
data suggest a pivotal role for ACE to regulate the balance of Ang II and Ang‐(1‐7), two peptides
within the RAS that exhibit strikingly different actions from one another [7].
4. Chymase
Chymases [EC 3. 4.21.39] comprise a family of serine peptidases that may generate Ang II by
hydrolysis of the Phe8‐His9 bond of Ang I and other peptide precursors [Ang‐(1‐12), Ang‐
(1‐25)] (α‐chymases) or metabolize Ang II at Tyr4‐Ile5 to form Ang‐(1‐4) and Ang‐(5‐8) (β‐
chymases) [34–39]. Humans express α‐chymase while rodents express primarily β‐chymases,
as well as other isoforms (mouse MCP‐4 and rat MCP‐5) that more closely resemble α‐chymase
in regard to the processing of Ang I to Ang II [35]. The human and mouse enzymes may also
play a role in the conversion of the endothelin precursor to the active peptide, as well as the
activation of various inflammatory cytokines [40]. Chymases (35 kDa) are synthesized and
stored in an inactive proform within mast cells and neutrophils that are released with other
proteases (cathepsin G, tryptases, and renin) upon degranulation following injury or inflam‐
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mation [41]. Although chymases are soluble enzymes, they associate with the cell membrane
and may locate to the extracellular surface of tissues following release. The serine protease
inhibitor chymostatin is typically used to demonstrate specificity; however, chymostatin
inhibits other Ang II-generating enzymes (cathepsin G and elastase-2). Thus, chymostatin
sensitivity for Ang II generation does not necessarily demonstrate the involvement of chymase
and more selective approaches should be considered [42–45]. The extent that chymase or other
peptidases participate in the formation of circulating or tissue Ang II through an ACE-
independent pathway remains equivocal [46].
5. Neprilysin
Neprilysin [EC 3.4.24.11; ~95 kDa] is a metalloendopeptidase that is predominantly anchored
to the plasma membrane. The peptidase was initially characterized in brain to hydrolyze the
opiate peptide enkephalin, hence the original terminology of the enzyme as “enkephalinase.”
Neprilysin was subsequently found in a number of peripheral tissues with particularly high
expression within the brush border on the apical region of the renal proximal tubules. Interest
in the renal expression of neprilysin reflected the potential role of the peptidase to metabolize
natriuretic peptides, and selective inhibitors alone or combined with an ACE inhibitor
(“vasopeptidase inhibitor”) were developed as cardiovascular therapies to prolong the renal
actions of these peptides [47–52]. Although the vasopeptidase inhibitor omapatrilat was
clinically withdrawn regarding a greater incidence of angioedema that may reflect increased
levels of bradykinin, a new generation of agents that combine a neprilysin inhibitor and an
AT1R antagonist may be a promising therapeutic approach for the treatment of heart failure
[53]. One potential caveat to this approach would be that the neprilysin inhibitor component
may reduce circulating levels of Ang-(1-7) and potentially attenuate the cardioprotective
effects of the combined antagonist/inhibitor.
Vascular neprilysin is responsible for the extracellular conversion of Ang I to Ang-(1-7) in the
circulation, particularly under conditions of chronic ACE inhibition (Figure 1) [54]. Neprilysin
hydrolyzes the Pro7-Phe8 bond of Ang I to form Ang-(1-7), as well as the Tyr4-Ile5 bond to
generate Ang-(1-4) that reflects the enzyme’s preference for aromatic and hydrophobic
residues. We further showed that renal neprilysin on the proximal tubules and the renal cortex
readily converted both Ang I and Ang-(1-12) to Ang-(1-7), as well as that a neprilysin inhibitor
attenuated the blood pressure-lowering effects of the ACE inhibitor lisinopril in the sponta-
neously hypertensive rat [33, 55, 56]. Apart from the conversion of Ang I to Ang-(1-7),
neprilysin is capable of metabolizing a number of other peptides including adrenomedullin,
Ang II [to Ang-(1-4)], endothelin, bradykinin, and the natriuretic peptides ANP and BNP.
6. Thimet oligopeptidase
Thimet oligopeptidase [EC 3.4.24.15, 80 kDa] is primarily a soluble metalloendopeptidase that
resides within the cell. Similar to neprilysin, thimet oligopeptidase prefers aromatic and
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hydrophobic residues and cleaves multiple peptide substrates. In regard to the RAS, thimet
oligopeptidase hydrolyzes Ang I exclusivity at the Pro-Phe bond to form Ang-(1-7) (Figure 1).
We recently showed that both neprilysin and thimet oligopeptidase contributed to the
processing of Ang I to Ang-(1-7) within isolated mitochondria [21]. In the human proximal
tubule HK-2 cell line, cytosolic thimet oligopeptidase was the sole activity responsible for the
generation of Ang-(1-7) from exogenous Ang I [57]. Moreover, thimet oligopeptidase activity
in isolated nuclei processed Ang I exclusively to Ang-(1-7) and may be a potential candidate
that contributes to the nuclear levels of Ang-(1-7) within the cell [22]. The RAS was originally
characterized as a classic endocrine or circulating system, but there is very compelling evidence
for the intracellular expression of the RAS peptides, receptors, and synthetic components [7,
54, 58–60]. It is presently unclear the cellular mechanisms for the intracellular expression of
Ang II or Ang-(1-7), although the intracellular peptidase thimet oligopeptidase may play a role
in the cellular Ang-(1-7) axis.
7. Angiotensin-converting enzyme 2
ACE2 is a membrane-bound monocarboxypeptidase [EC 3.4.17.23; 120 kDa] that converts Ang
II directly to Ang-(1-7) (Figure 1). ACE2 was initially characterized as a homolog to ACE and
exhibits approximately ~40% homology with ACE [60–62]. ACE2 was initially reported to
cleave Ang I not to Ang II, but to the nonapeptide Ang-(1-9) [63]. Subsequent studies found
that Ang II exhibits far better kinetic values for ACE2 that would argue that the endogenous
substrate is Ang II, not Ang I [64]. Among a number of peptide substrates (>100) that were
screened for ACE2, Vickers et al. reported that only apelin 13 exhibited comparable kinetic
values to that of Ang II [65]. In the murine heart, Ang II was primarily converted to Ang-(1-7)
by ACE2 and that in the presence of the ACE2 inhibitor MLN-4760 or in ACE2 null mice there
was essentially no metabolism of Ang II in the heart [66]. By contrast, under identical kinetic
conditions, Ang I was primarily converted to Ang-(1-9) by carboxypeptidase A and not ACE2
in both the wild-type and ACE2 knockout mice.
In comparison to ACE, the circulating levels of ACE2 are typically quite low. Whether this
reflects a reduced degree of shedding, lower vascular expression or both is not presently clear.
Rice et al. reported that the molar concentration of ACE in human serum averaged 7 nM in
over 500 subjects while ACE2 content was 200-fold lower (33 pM) and was detectable in <10%
of the patient population [67]. Circulating NEP content (290 pM) was also lower than ACE and
evident in <30% of these patients [67]. Serum and urinary ACE2 activities are elevated in
diabetes, heart failure, and hypertension [68–70]. Circulating ACE2 activity increased approx-
imately threefold in the diabetic hypertensive mRen2.Lewis rat; however, serum ACE activity
also increased in the diabetic rats. As measured under identical kinetic conditions, serum ACE
was far higher than ACE2 suggesting that the capacity to generate Ang II (or metabolize Ang-
(1-7) and bradykinin) remains greater than the capability to form Ang-(1-7) from Ang II [68].
Similar to ACE, ACE2 has a potentially significant role in the RAS pathway as a single catalytic
step metabolizes Ang II to attenuate the Ang II-AT1 receptor pathway, and generate Ang-(1-7)
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that would stimulate the Ang-(1-7)-AT7/Mas receptor axis (Figure 1) [71, 72]. Indeed, ACE2-
deficient animals exhibit exaggerated responses to Ang II or under chronic conditions of an
activated RAS [73–76]. In turn, overexpression of ACE2 or administration of the soluble form
of the peptidase, which retains full enzymatic activity, attenuates the Ang II-dependent
increase in blood pressure and indices of target organ injury [77–85]. In regard to the benefits
of an activated ACE2 pathway, several compounds have been identified that may act as
allosteric activators of ACE2 including xanthenone (XNT) and diminazene aceturate (DIZE)
to promote a higher ratio of Ang-(1-7) to Ang II [86]. Chronic treatment with DIZE ameliorated
the extent of pulmonary hypertensin and fibrosis, renal tissue injury, and myocardial infarction
consistent with enhanced levels of Ang-(1-7) and a reduction in Ang II [84, 87–90]. Interestingly,
DIZE treatment was also associated with increased mRNA levels of ACE2 suggesting that
DIZE may exhibit actions apart from the direct activation of the peptidase [87, 91]. However,
it should be noted that the effects of DIZE on ACE2 activity or expression have not been
confirmed by others. Haber et al. [92] found no effect of DIZE on soluble ACE2 activity or an
influence on Ang II-dependent hypertension using similar doses of DIZE as previously
reported. Velkosa et al. [93] also found no direct effect of various concentrations of DIZE on
renal ACE2 activity and slightly increased renal ACE2 activity in the 5/6 nephrectomized rat
following a 2-week administration. Of particular interest, the Velkosa study reported that DIZE
normalized the marked increase in renal ACE activity suggesting that ACE may be a more
relevant target than ACE2 [93]. DIZE also failed to increase ACE2 activity or enhance the local
vascular actions of Ang-(1-7) in the isolated pig coronary arteries [94].
Conceptually, the use of ACE2 as a therapeutic agent to chronically alter the balance of Ang II
and Ang-(1-7) is challenging. ACE activity in the circulation and the vasculature surface is
significant with a very high capacity to generate Ang II. This reflects not simply the abundance
of ACE but the significant capability of angiotensinogen and renin to generate the ACE
substrate Ang I. Moreover, reduced Ang II levels by exogenous ACE2 should stimulate the
generation of Ang II that reflects the activation of negative feedback mechanisms on renin.
Therefore, it is difficult to conceive sufficiently high levels of ACE2 that can be achieved to
chronically reduce Ang II and increase Ang-(1-7) except with the possible addition of an ACE
inhibitor. In this case, supplementation of ACE2 may degrade residual levels of Ang II and the
circulating levels of Ang-(1-7) may be augmented, particularly as the Ang-(1-7)-degrading
pathway in the circulation is attenuated by the ACE inhibitor.
8. Dipeptidyl peptidase 3
We demonstrated a role for ACE in the metabolism of Ang-(1-7), but there are other potential
pathways that may regulate endogenous levels of the peptide [95]. Marshall and colleagues
reported that ACE and a second peptidase activity in the sheep cerebrospinal fluid degraded
Ang-(1-7) [95–97]. Interestingly, the non-ACE-degrading activity accounted for a greater
contribution of metabolism than ACE [96]. Moreover, this activity was inversely correlated to
CSF levels of Ang-(1-7) in control and betamethasone-exposed sheep, a model of fetal pro-
gramming that exhibits elevated blood pressure and an attenuated baroreflex [7]. Subsequent
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studies found the Ang-(1-7)-degrading activity in sheep brain and kidney cortex, as well as in
the human proximal tubule HK-2 cell line [57, 98]. The enzyme activity exhibited unusual
characteristics as Ang I and other peptides equal to or greater than 10 residues were not
substrates for the peptidase [57, 98]. In addition, the peptidase was sensitive to both chelating
agents such as o-phenanthroline and EDTA, and the sulfhydryl inhibitors APMA and PCMB
[57, 98]. Additional studies identified the inhibitor JMV-390, originally developed to block the
metalloendopeptidases neprilysin, thimet oligopeptidase, and neurolysin, that potently
inhibited the Ang-(1-7)-degrading activity in the brain and kidney [IC50 <1 nM] [57, 98].
Conversely, specific inhibitors against these endopeptidases did not attenuate the Ang-(1-7)-
degrading activity [98]. Interestingly, the peptidase activity accounted for the sole degradative
pathway in the cytosolic fraction and in the media of the HK-2 cells [57]. Utilizing the HK-2
cells as the source of the Ang-(1-7)-degrading activity, we recently purified the peptidase from
the cell cytosol by ion exchange and hydrophobic interaction chromatography and identified
the enzyme as dipeptidyl peptidase 3 [EC 3.4. 14.4, DPP 3] [99].
DPP 3 belongs to a family of metalloaminopeptidases that sequentially cleave two residues
from the N-terminus of peptides no more than eight residues in length and this likely explains
our previous results that Ang I, apelin-13, and neurotensin were not substrates for the Ang-
(1-7)-degrading activity in the CSF and brain [98]. We obtained a human recombinant form of
Figure 2. Kinetics of human DPP 3 hydrolysis of Ang-(1-7) and Ang-(3-7). (A) Chromatographs reveal that human DPP
3 cleaves Ang-(1-7) to the tripeptide Ang-(5-7). (B) Chromatograph reveals that the JMV-390 inhibitor attenuates Ang-
(1-7) metabolism by human DPP 3. (C) Kinetic analysis of the hydrolysis of Ang-(1-7) and Ang-(3-7) by human DPP 3.
Data adapted from Cruz-Diaz et al. [99].
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DPP 3 to show that the enzyme metabolized Ang-(1-7) in two cleavage steps [99]. DPP 3 initially
hydrolyzes Ang-(1-7) at the Arg2-Val3 bond to form Ang-(3-7) and the dipeptide Arg1-Asp2.
Ang-(3-7) is then very rapidly cleaved at Tyr4-Ile5 to form Ang-(5-7) and Val3-Tyr4. The kinetic
analysis of DPP 3 hydrolysis revealed a higher efficiency constant (kcat/km) for Ang-(3-7) than
Figure 3. The JMV-390 inhibitor reduces DPP 3 activity and alters Ang-(1-7) cellular content of HK-2 cells. (A) Increas-
ing doses of the JMV-390 inhibitor reduced DPP 3 activity (125I-Ang-(3-4) generation—fmol/min/mg protein) in HK-2
cells. (B) Low-dose JMV-390 (20 nM) tended to increase the cellular content of Ang-(1-7) (fmols/mg protein), but high
dose (200 nM) significantly reduced Ang-(1-7). *P < 0.05 versus control; #P < 0.05 versus 20 nM JMV. Data adapted from
Cruz-Diaz et al. [99].
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Ang-(1-7) (Figure 2) [99]. The preferred hydrolysis of Ang-(3-7) by DPP 3 would account for
our inability to demonstrate the accumulation of Ang-(3-7) following the initial metabolism of
Ang-(1-7). In regard to an in vivo role for DPP 3 to modulate Ang-(1-7), human HK-2 cells were
treated with varying doses of the JMV-390 inhibitor and we assessed both the endogenous
content of Ang-(1-7) and the intracellular DPP-3/Ang-(1-7)-degrading activity in the cells. As
shown in Figure 3, 20- and 200-nM JMV-390 reduced DPP3 activity by >30 and >80%, respec-
tively, as compared to control suggesting that the inhibitor effectively penetrates the cells [99].
The lower dose of JMV increased the cellular content Ang-(1-7) approximately twofold,
although this did not reach statistical significance. The higher dose of JMV, however, signifi-
cantly reduced the intracellular levels of the peptide [99]. We interpret the latter results that
the high dose may spill over to block other peptidases including thimet oligopeptidase that
may be involved in the generation of Ang-(1-7) in the renal cells [57]. Thus, the blockade of
Ang-(1-7)-forming enzymes by the high-dose JMV may override any protective effects of DPP
3 inhibition. We are currently assessing alternative approaches to block DPP 3 within the HK-2
cells and assess both secreted and intracellular levels of Ang-(1-7), as well as Ang-(1-7)-
dependent actions on these cells.
9. AGE-induced peptidase
Our recent studies assessed the potential role of Ang-(1-7) in the progression of epithelial-to-
mesenchymal transition (EMT) in the renal epithelial NRK-52 cell line by either advanced
glycation end products (AGEs) or the cytokine TGF-β [100]. Ang-(1-7) essentially abolished
the cellular indices for EMT in the NRK-52 cells likely through the inhibition of the nonca-
nonical ERK 1/2-signaling pathway stimulated by AGE (100). Interestingly, AGE exposure
reduced the intracellular levels of Ang-(1-7) but did not alter the cellular content of Ang II
[100]. Processing of Ang I to Ang-(1-7) by thimet oligopeptidase tended to be reduced by AGE;
however, the intracellular metabolism of Ang-(1-7) to Ang-(1-4) was significantly increased by
AGE exposure [100]. These data suggest that AGE-induced EMT may reflect lower Ang-(1-7)
tone in the renal epithelial cells that may be permissive for the progression of EMT and the
increase in tissue fibrosis. Our preliminary data suggest that DPP 3 is not responsible for the
AGE-induced metabolism of Ang-(1-7) in these cells and that another peptidase activity may
participate in the cellular metabolism of the peptide. As shown in Figure 4A, the NRK-52
cytosolic fraction readily hydrolyzed the quenched Ang-(1-7) fluorescent substrate Abz1-Ang-
(1-7)-Tyr7(NO2) to Abz-Ang-(1-4). By contrast, DPP 3 in the HK-2 renal cells did not cleave the
Ang-(1-7) fluorescent peptide (Figure 4B). The failure of DPP 3 to cleave the fluorescent Ang-
(1-7) substrate is consistent with the inability of DPP 3 to hydrolyze blocked N-terminal
residues of peptides such as the Abz moiety on the Ang-(1-7) substrate. Moreover, hydrolysis
of the N-terminally blocked Ang-(1-7) fluorescent substrate by the cytosolic fraction of the
NRK-52 cells suggests the peptidase is likely an endopeptidase. Apart from the identification
of the Ang-(1-7)-degrading activity in the NRK-52E cells, it remains to be determined whether
intracellular levels of Ang-(1-7) influence the EMT process.
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Figure 4. Metabolism of Abz1-Ang-(1-7)-Tyr7 (NO2). (A) HPLC chromatograph reveals that the cytosolic fraction of the
NRK-52E cells cleaves the Ang-(1-7)-fluorescent substrate Abz-Ang-(1-7) to Abz-Ang-(1-4). (B) By contrast, HK-2 cyto-
solic fraction does not hydrolyze the Ang-(1-7)-fluorescent substrate suggesting an endopeptidase activity distinct
from DPP 3. The large void peak is absorbance from the DMSO solvent to dissolve the fluorescent substrate. Substrate
concentration and incubation conditions are identical for both cell types. The HK-2 cell data are adapted from Wilson
et al. [57].
10. Characterization of peptidase pathways
In the review of the peptidases of the Ang-(1-7) axis, a brief discussion of the various bio-
chemical approaches to characterize these enzymatic components is warranted. Ideally,
utilization of the endogenous peptide substrates including Ang I, Ang II, and Ang-(1-7) should
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be assessed to identify the peptidase activities involved in the RAS [101]. One advantage is
that the contribution of various peptidases for a given peptide is directly comparable to
determine the predominant pathway in a particular tissue or treatment condition. Peptidase
activities derived by different synthetic substrates are not comparable unless standardized to
the enzyme concentration. Moreover, the use of endogenous peptide substrates may reveal
novel peptidase activities involved in angiotensin processing [102, 103]. Peptidase assays
developed in our laboratory typically utilize 125I-radiolabled peptides coupled to high-
performance liquid chromatography (HPLC)-based separation and automated in-line γ-
detection. Advantages of this are that only microliter amounts of serum or microgram
quantities of tissue are normally required that reflects detection sensitivity in the fmol range
and the lack of detector interference or quenching [33].
More recent studies have incorporated mass spectroscopy (MS) detection of angiotensin
metabolism in tissues, cells, and plasma, as well as the derivation of processing networks [104].
Velez and colleagues applied HPLC-MS analysis of Ang I processing in rat glomeruli to reveal
the predominant processing of Ang I to Ang-(1-7) catalyzed by neprilysin [104]. Interestingly,
the authors could not demonstrate an Ang I to Ang II pathway even following the blockade
of the Ang-(1-7) pathway with a neprilysin inhibitor. Hildesbrand et al. [103] utilized a HPLC-
tandem quadrupole system (HPLC-MS/MS) to reveal multiple metabolism pathways from
Ang I to its N-terminal metabolites Ang-(5-10) and Ang-(4-10), as well as Ang II and Ang-(1-7)
in immobilized proteins from human plasma. Suski et al. [105] reported that Ang I was
primarily converted to Ang-(1-7) in vascular smooth muscle cells (VSMCs) as characterized
by HPLC-MS/MS and confirms our earlier study that thimet oligopeptidase directly processed
Ang I to Ang-(1-7) in rat VSMC [106]. Grobe and colleagues have applied “in situ” MALDI to
characterize both renal and cardiac metabolism of exogenous Ang II [107, 108]. Ang-(1-7) was
the primary product from Ang II in the renal cortex while Ang III was the major metabolite in
the medulla [108]. In the heart, Ang III and Ang-(1-7) were products of Ang II metabolism
catalyzed by APA and ACE2, respectively [107]. These data confirm earlier HPLC-based
studies on the contribution of ACE2 to Ang-(1-7) formation in the mouse and human heart [66,
109]. Although this approach cannot distinguish intracellular versus membrane or extracel-
lular processing and requires relatively high-substrate concentrations, it is likely that these
systems will develop the required sensitivity and resolution to detect peptides in situ, as well
as characterize the extent of enzymatic processing.
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